QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:OMGA

Omega Therapeutics (OMGA) Stock Forecast, Price & News

$2.30
+0.05 (+2.22%)
(As of 09/28/2023 ET)
Compare
Today's Range
$2.14
$2.37
50-Day Range
$2.25
$5.68
52-Week Range
$2.11
$11.98
Volume
73,927 shs
Average Volume
122,363 shs
Market Capitalization
$126.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Omega Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
378.3% Upside
$11.00 Price Target
Short Interest
Bearish
10.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.61mentions of Omega Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.14) to ($2.18) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars


OMGA stock logo

About Omega Therapeutics (NASDAQ:OMGA) Stock

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

OMGA Price History

OMGA Stock News Headlines

Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
Omega Therapeutics Inc.
Piper Sandler Keeps Their Buy Rating on Omega Therapeutics (OMGA)
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
OMGA - Omega Therapeutics, Inc.
Jefferies Reaffirms Their Buy Rating on Omega Therapeutics (OMGA)
See More Headlines
Receive OMGA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omega Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OMGA Company Calendar

Last Earnings
8/03/2023
Today
9/28/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OMGA
Fax
N/A
Employees
116
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+378.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-102,700,000.00
Net Margins
-4,283.72%
Pretax Margin
-4,283.72%

Debt

Sales & Book Value

Annual Sales
$2.07 million
Book Value
$2.21 per share

Miscellaneous

Free Float
23,710,000
Market Cap
$126.82 million
Optionable
Not Optionable
Beta
0.74
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Mahesh Karande (Age 49)
    Pres, CEO & Board Director
    Comp: $812.88k
  • Ms. Ling Zeng Esq. (Age 54)
    J.D., Chief Legal & Admin. Officer and Sec.
    Comp: $519.36k
  • Dr. Yan Moore M.D. (Age 56)
    Chief Medical Officer
    Comp: $1.14M
  • Mr. Joshua Reed M.B.A. (Age 50)
    Chief Financial Officer
  • Dr. Sivakesava Sakhamuri Ph.D.
    Sr. VP and Head of Technical Operations & Quality
  • Dr. Thomas McCauley (Age 54)
    Chief Scientific Officer
  • Mr. Charles O'Donnell Ph.D.
    VP and Head of Computational Genomics & Data Sciences
  • Ms. Ramola Bhandarkar
    Sr. VP of Regulatory Affairs













OMGA Stock - Frequently Asked Questions

Should I buy or sell Omega Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omega Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OMGA shares.
View OMGA analyst ratings
or view top-rated stocks.

What is Omega Therapeutics' stock price forecast for 2023?

4 analysts have issued 1 year price objectives for Omega Therapeutics' stock. Their OMGA share price forecasts range from $10.00 to $12.00. On average, they anticipate the company's share price to reach $11.00 in the next year. This suggests a possible upside of 378.3% from the stock's current price.
View analysts price targets for OMGA
or view top-rated stocks among Wall Street analysts.

How have OMGA shares performed in 2023?

Omega Therapeutics' stock was trading at $5.71 on January 1st, 2023. Since then, OMGA shares have decreased by 59.7% and is now trading at $2.30.
View the best growth stocks for 2023 here
.

When is Omega Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our OMGA earnings forecast
.

How were Omega Therapeutics' earnings last quarter?

Omega Therapeutics, Inc. (NASDAQ:OMGA) released its earnings results on Thursday, August, 3rd. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.03. The firm had revenue of $0.76 million for the quarter, compared to analysts' expectations of $0.63 million. Omega Therapeutics had a negative trailing twelve-month return on equity of 97.34% and a negative net margin of 4,283.72%.

When did Omega Therapeutics IPO?

(OMGA) raised $126 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share.

What is Omega Therapeutics' stock symbol?

Omega Therapeutics trades on the NASDAQ under the ticker symbol "OMGA."

Who are Omega Therapeutics' major shareholders?

Omega Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.92%), Platinum Investment Management Ltd. (1.61%), 683 Capital Management LLC (0.86%), Geode Capital Management LLC (0.80%), State Street Corp (0.71%) and Northern Trust Corp (0.37%). Insiders that own company stock include Flagship Pioneering Inc and Richard A Young.
View institutional ownership trends
.

How do I buy shares of Omega Therapeutics?

Shares of OMGA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omega Therapeutics' stock price today?

One share of OMGA stock can currently be purchased for approximately $2.30.

How much money does Omega Therapeutics make?

Omega Therapeutics (NASDAQ:OMGA) has a market capitalization of $126.82 million and generates $2.07 million in revenue each year. The company earns $-102,700,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis.

How many employees does Omega Therapeutics have?

The company employs 116 workers across the globe.

How can I contact Omega Therapeutics?

Omega Therapeutics' mailing address is 20 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The official website for the company is www.omegatherapeutics.com. The company can be reached via phone at 617-949-4360 or via email at argotomega@argotpartners.com.

This page (NASDAQ:OMGA) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -